Detection, Control, and Management of a Respiratory Syncytial Virus Outbreak in a Pediatric Hematology-Oncology Department


Shachor-Meyouhas Y., Zaidman I., Kra-Oz Z., Arad-Cohen N., Kassis I.

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, cilt.35, ss.124-128, 2013 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 35 Konu: 2
  • Basım Tarihi: 2013
  • Doi Numarası: 10.1097/mph.0b013e3182756edc
  • Dergi Adı: JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY
  • Sayfa Sayıları: ss.124-128

Özet

Background: Immunocompromised patients are at increased risk for severe respiratory syncytial virus (RSV) infection. Palivizumab is approved for prevention of RSV in specific populations but not for treatment. Few studies demonstrated the safety and successful treatment with intravenous (IV) palivizumab. We describe our experience with IV palivizumab treatment for RSV in a pediatric hematology-oncology department during an outbreak.